Compare AbbVie Inc (ABBV) vs Avantis International Small Cap Value ETF (AVDV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Avantis International Small Cap Value ETF — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Avantis International Small Cap Value ETF trades at $103.11. The key difference: AbbVie Inc pays a 2.72% dividend while Avantis International Small Cap Value ETF pays none, and AbbVie Inc is trading nearer its 52-week high, Avantis International Small Cap Value ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | AVDV | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Sector/Thematic |
52-Week High | $261.07 | $110.40 |
52-Week Low | $184.85 | $80.02 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
AVDV trades at $105.77, up 1.29% today, with a bullish technical signal from moving averages. The ETF focuses on international small-cap value stocks, delivering strong performance with 35% gains highlighted in recent coverage. Dividend payments provide additional investor returns, with the next $1.39 distribution scheduled for June 2026.
Outlook remains positive given international small-cap value momentum, though cyclical sector exposure and reliance on regional factors present risks. Structural alpha concerns noted by analysts suggest monitoring performance drivers beyond broad market trends for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Avantis International Small Cap Value ETF
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →
